CHNA
Loncar China BioPharma ETF
Loncar China BioPharma TR USD
NAV as of
4 Week: 17.84 - 19.79
52 Week: 13.50 - 22.53
Latest Closing Price
18.68
Premium / Discount
0.06
Expense Ratio
0.79%
Investment Objective
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -0.48 | 2.78 | -0.17 |
| 1 Day | 4.70 | 0.00 | 0.00 |
| 1 Week | -0.59 | 9.98 | -0.06 |
| 1 Month | -4.94 | 12.13 | -0.41 |
| 3 Months | 2.17 | 23.29 | 0.09 |
| 6 Months | 24.86 | 37.34 | 0.67 |
| 1 Year | -10.45 | 50.35 | -0.21 |
| 2 Years | -50.18 | 64.89 | -0.77 |
| 3 Years | -12.22 | 71.29 | -0.17 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 30.6631 | 34.3839 | -9.4178 | -28.0018 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 45.0000 | 48.0000 | 50.0000 | 68.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 28/12/2021 | 30/12/2021 | 3.0314 |
| 22/12/2019 | 25/12/2019 | 0.0403 |
Portfolio Data
Total Number of Holdings: 69
Number of Bond Holdings: 0
Number of Equity Holdings: 66
Total Market Value: 5,632,269
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | AIM Vaccine Co Ltd Class H | 2.9950 | 32,000 | 0 | 168,577 |
| 2 | Sino Biopharmaceutical Ltd | 2.3699 | 238,500 | 0 | 133,390 |
| 3 | Hansoh Pharmaceutical Group Co Ltd | 2.2317 | 68,000 | 0 | 125,617 |
| 4 | CSPC Pharmaceutical Group Ltd | 2.2195 | 122,880 | 0 | 124,927 |
| 5 | BeiGene Ltd ADR | 2.1941 | 553 | 0 | 123,496 |
| 6 | Sinopharm Group Co Ltd | 2.1938 | 40,300 | 0 | 123,479 |
| 7 | Shanghai Fosun Pharmaceutical (Group) Co Ltd Class | 2.1810 | 44,000 | 0 | 122,763 |
| 8 | China Resources Pharmaceutical Group Ltd Registere | 2.0758 | 126,500 | 0 | 116,842 |
| 9 | Shanghai Pharmaceuticals Holding Co Ltd Class H | 1.9481 | 56,400 | 0 | 109,649 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 5.89 |
| Large | 34.49 |
| Medium | 39.95 |
| Small | 14.99 |
| Micro | 4.70 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
12.9569
Price/Book*
1.9210
Price/Sales*
0.9840
Price/Cash Flow*
11.3537
Dividend Yield*
1.1649
Growth Measures
Long-Term Earnings
16.7686
Historical Earnings
14.1499
Sales Growth
6.3067
Cash-Flow Growth
-7.7127
Book-Value Growth
1.6654
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
